Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs Schedule

As a benefit for attending the 32nd Annual Meeting and Pre-Conference Programs, SITC provides enduring materials free of charge for the specific programs attended. If you are a SITC member, or member of the general public, but did not register to attend a Pre-Conference program or the 32nd Annual Meeting, the materials are available for purchase by clicking here.

Presentations and video recordings are available based on permission from presenters.

no_symbol.png  Presentations with this symbol indicate that the presenter did not grant permission to the presentation. 


Wednesday, Nov. 8

8 – 8:15 a.m.

Welcome and Introductions
Lisa H. Butterfield, PhD – University of Pittsburgh

Session I: Biomarkers in Development

General Biomarkers
8:15 – 8:25 a.m. Immune Report Card
Carl Morrison, MD, DVM – OmniSeq, Inc.
8:25 – 8:35 a.m. Multiplex IHC Immuno-Oncology Panel for Standardized Profiling of the Immune Status Based on Spatial and Functional Characterization of the Tumor Microenvironment
Svenja Lippok, PhD – Definiens AG
8:35 – 8:45 a.m. Exosome Repertoires and Cargo Associated with Tumor Progression and Responses to Treatment
Jennifer Jones, MD, PhD – National Institutes of Health
8:45 – 8:55 a.m. A Biomarker-Driven Approach for the Development of the ICOS Agonist Antibody, JTX-2011
Heather Hirsch, PhD – Jounce Therapeutics, Inc.
8:55 – 9:10 a.m. Group Discussion

Biomarkers Supporting Primarily Immune Checkpoint Blockade
9:10 – 9:20 a.m. Composite Predictors of Efficacy to Checkpoint Inhibitors and Mechanisms of Immune Escape, Informing Combination Strategies via Personalized Cancer Immunotherapy
Priti Hedge, PhD – Genetech
9:20 – 9:30 a.m. Pretreatment Gene Expression Correlation with Clinical Response to no_symbol.pngPembrolizumab or Nivolumab in Metastatic Melanoma
Tobias Schatton, PharmD, PhD – Brigham Women's Hospital
9:30 – 9:40 a.m. Calibration of FoundationOne® with Whole Exome Sequencing for Assessment of Tumor Mutation Burden as a Biomarker for Response to Immune Checkpoint Inhibitorsno_symbol.png
Joseph D. Szustakowski, PhD – Bristol-Meyers Squibb
9:40 – 9:50 a.m. Biomarkers for Primary Immunotherapy Resistance Based on the Circulating Proteome
Heinrich Roder, PhD – Biodesix Inc.
9:50 – 10:05 a.m. Group Discussion
10:05 – 10:20 a.m. Break

Biomarkers Supporting Primarily T Cell Interventions
10:20 – 10:30 a.m. Pharmacodynamic and Predictive Biomarkers Supporting Development of CAR T Cells for the Treatment of B cell Malignancies
John Rossi, MSc – Kite Pharma, Inc.
10:30 – 10:40 a.m. Single T cell Functional Response Biomarkers to Differentiate Responders and Non-Responders in CAR-T and Checkpoint Based cancer Immunotherapies
Sean Mackay – Isoplexis
10:40 – 10:50 a.m. Standardized Immune-Based Diagnostic Tests to Predict the Risk of Recurrence and Response to Therapy of Cancer Patients
Fabienne Hermitte, PhD – HalioDx
10:50 – 11 a.m. Public NY-ESO-1 Specific TCRs as Novel Biomarkers for Immune Monitoring of NY-ESO-1 Positive Cancer Patientsno_symbol.png
Hailing Lu, MD, PhD – Immune Design
11 – 11:15 a.m. Group Discussion
11:15 – 11:30 a.m. Break

Session II: Strategic Considerations of Biomarkers
11:30 – 11:45 a.m. Regulatory Perspective
Gideon Blumenthal, MD – Food & Drug Administration
11:45 – 12:25 p.m.

Panel Discussion
Jérôme Galon, PhD – INSERM - Cordeliers Research Center
Francesco Marincola, MD – AbbVie Inc.
Minkyung Song, PhD – National Cancer Institute
12:25 – 12:30 p.m. Closing Remarks